Background
Background Despite a growing use of Despite a growing use of selective serotonin reuptake inhibitors in selective serotonin reuptake inhibitors in older people, only one trial has examined older people, only one trial has examined their prophylactic efficacy in people aged their prophylactic efficacy in people aged 65 years and over. 65 years and over.
Aims Aims To examine the efficacy of
To examine the efficacy of sertraline in preventing the recurrence of sertraline in preventing the recurrence of depression in older people living in the depression in older people living in the community. community.
Method
Method Participants were openly Participants were openly treated with sertraline and then treated with sertraline and then randomised into a double-blind, placebo-randomised into a double-blind, placebocontrolled continuation/maintenance controlled continuation/maintenance study of about 2 years duration.Drug study of about 2 years duration.Drug dosage was maintained at levels that dosage was maintained at levels that achieved remission. achieved remission.
Results

Results No significant difference
No significant difference between the sertraline and placebo between the sertraline and placebo groups was found in the proportion of groups was found in the proportion of recurrences ( recurrences (7 77.9%; 95% CI^28.06 to 7.9%; 95% CI^28.06 to 12.23).Increased age and minor residual 12.23).Increased age and minor residual symptoms during the continuation phase symptoms during the continuation phase were associated with recurrence. were associated with recurrence.
Conclusions Conclusions Sertraline attherapeutic
Sertraline attherapeutic dosage does not provide significant dosage does not provide significant protection against recurrence. protection against recurrence.
Declaration of interest Declaration of interest The study
The study was sponsored by Pfizer Ltd. was sponsored by Pfizer Ltd.
Up to a tenth of people living in the Up to a tenth of people living in the community who are aged 65 years or more community who are aged 65 years or more suffer from depression severe enough to suffer from depression severe enough to warrant intervention. Just under 2% suffer warrant intervention. Just under 2% suffer from major depression (Beekman from major depression (Beekman et al et al, , 1999) likely to be alleviated by anti-1999) likely to be alleviated by antidepressant therapy. Depression is asso-depressant therapy. Depression is associated with long-term morbidity and ciated with long-term morbidity and increased mortality (Davidson increased mortality (Davidson et al et al, , 1988) . Epidemiological studies indicate 1988). Epidemiological studies indicate that up to 10% of older community resi-that up to 10% of older community residents with depression are treated with anti-dents with depression are treated with antidepressants. There is a growing trend in the depressants. There is a growing trend in the use of selective serotonin reuptake inhibi-use of selective serotonin reuptake inhibitors (Wilson tors (Wilson et al et al, 1999) , and a recent study , 1999), and a recent study has demonstrated efficacy of maintenance has demonstrated efficacy of maintenance with citalopram (Klysner with citalopram (Klysner et al et al, 2002) in this , 2002) in this age group. This is the first placebo-age group. This is the first placebocontrolled trial examining the efficacy of controlled trial examining the efficacy of sertraline in the prevention of recurrence of sertraline in the prevention of recurrence of depression in older people in the community. depression in older people in the community.
METHOD METHOD
Study design Study design
The study consisted of a treatment phase (8 The study consisted of a treatment phase (8 weeks) and a continuation phase (16-20 weeks) and a continuation phase (16-20 weeks) during which participants were weeks) during which participants were treated with open-label sertraline prior to treated with open-label sertraline prior to randomisation into a double-blind, parallel, randomisation into a double-blind, parallel, placebo-controlled maintenance trial of placebo-controlled maintenance trial of 100 weeks. During the open phases drug 100 weeks. During the open phases drug dosage was titrated from 50 mg to dosage was titrated from 50 mg to 200 mg daily, as clinically indicated. All 200 mg daily, as clinically indicated. All participants were maintained on their final participants were maintained on their final therapeutic dosage (or placebo equivalent) therapeutic dosage (or placebo equivalent) during the randomised, controlled phase during the randomised, controlled phase of the study, with the exception of those of the study, with the exception of those treated with 200 mg. In the latter cases the treated with 200 mg. In the latter cases the maintenance dosage was decreased from maintenance dosage was decreased from 200 mg to 150 mg, and each case was paired 200 mg to 150 mg, and each case was paired (by a third party) with a placebo recipient to (by a third party) with a placebo recipient to maintain double-blind conditions. maintain double-blind conditions.
Power analyses Power analyses
The power of the study was initially based The power of the study was initially based on recruiting 300 persons to each group. on recruiting 300 persons to each group. This was recalculated as the results from a This was recalculated as the results from a similar study became available (Doogan similar study became available (Doogan & Caillard, 1992) . This informed a new & Caillard, 1992) . This informed a new power calculation, indicating that a group power calculation, indicating that a group size of 60 would detect a 26% difference size of 60 would detect a 26% difference between groups with 95% confidence and between groups with 95% confidence and 80% power, assuming a 50% relapse/ 80% power, assuming a 50% relapse/ recurrence rate in the placebo group. This recurrence rate in the placebo group. This would also enable detection of relative risk would also enable detection of relative risk for relapse of 0.5 for sertraline compared for relapse of 0.5 for sertraline compared with placebo. with placebo.
Inclusion and exclusion criteria Inclusion and exclusion criteria
All participants were aged 65 years or All participants were aged 65 years or more. Psychiatric diagnoses were estab-more. Psychiatric diagnoses were established by a trained psychiatrist using criteria lished by a trained psychiatrist using criteria including Geriatric Mental State AGECAT including Geriatric Mental State AGECAT depression level 3 or over (Copeland depression level 3 or over (Copeland et al et al, , 1988) , DSM-III-R diagnoses of major 1988), DSM-III-R diagnoses of major depressive disorder (American Psychiatric depressive disorder (American Psychiatric Association, 1987) and a Hamilton Rating Association, 1987) and a Hamilton Rating Scale for Depression (HRSD) 17-item score Scale for Depression (HRSD) 17-item score of 18 or over (Bech of 18 or over (Bech et al et al, 1981) . Exclusion , 1981) . Exclusion criteria were a Mini-Mental State Examin-criteria were a Mini-Mental State Examination (MMSE) score (Folstein ation (MMSE) score (Folstein et al et al, 1975) , 1975) of 11 or under to exclude people with of 11 or under to exclude people with severe cognitive dysfunction; severe and un-severe cognitive dysfunction; severe and unstable physical illness; clinically significant stable physical illness; clinically significant alcohol misuse; significant suicidal or de-alcohol misuse; significant suicidal or delusional experiences; and concomitant drug lusional experiences; and concomitant drug treatment, including other psychotropic treatment, including other psychotropic drugs, warfarin and anticonvulsants. drugs, warfarin and anticonvulsants.
Randomisation, allocation Randomisation, allocation concealment and compliance concealment and compliance
A company independent of the sponsor and A company independent of the sponsor and trialist was responsible for packaging the trialist was responsible for packaging the trial drugs and randomisation. A computer-trial drugs and randomisation. A computergenerated randomisation list was provided generated randomisation list was provided by Pfizer Ltd. The list was stratified by by Pfizer Ltd. The list was stratified by dosage and used to produce numbered con-dosage and used to produce numbered containers for the identical capsules of either tainers for the identical capsules of either sertraline or placebo. Participants eligible sertraline or placebo. Participants eligible for the maintenance phase were allocated for the maintenance phase were allocated to the next number at their dose level. to the next number at their dose level. Codes were maintained in opaque, sealed Codes were maintained in opaque, sealed envelopes. They were broken on trial com-envelopes. They were broken on trial completion, after locking the study database. pletion, after locking the study database. External research auditors maintained the External research auditors maintained the security of the codes, and verified data security of the codes, and verified data collection and cleaning. Drug compliance collection and cleaning. Drug compliance was monitored through tablet counting at was monitored through tablet counting at each assessment and asking the patient if each assessment and asking the patient if any doses were missed. any doses were missed.
Sample recruitment Sample recruitment
Participants were recruited from the screen-Participants were recruited from the screening of all patients over 65 years of age at a ing of all patients over 65 years of age at a multi-partner general practice, and refer-multi-partner general practice, and referrals from: a community survey conducted rals from: a community survey conducted at the same time as the trial; twenty general at the same time as the trial; twenty general practices in Liverpool; and four old age practices in Liverpool; and four old age psychiatry teams. psychiatry teams.
Assessments and interviews Assessments and interviews
A trained psychiatrist conducted the initial, A trained psychiatrist conducted the initial, end-of-phase and final assessments, includ-end-of-phase and final assessments, including DSM-III-R criteria and final HRSD ing DSM-III-R criteria and final HRSD scores. Initial assessment included research scores. Initial assessment included research diagnostic and entry criteria, a physical diagnostic and entry criteria, a physical examination and laboratory investigations, examination and laboratory investigations, comprising blood count, , 1990) . Domiciliary interviews were con-1990) . Domiciliary interviews were conducted fortnightly during the first two ducted fortnightly during the first two phases of the study, monthly for the first phases of the study, monthly for the first 6 months of the maintenance phase and 6 months of the maintenance phase and subsequently every 2 months. All parti-subsequently every 2 months. All participants entered into the maintenance phase cipants entered into the maintenance phase were followed up, including those sub-were followed up, including those subsequently withdrawn from the trial. sequently withdrawn from the trial.
Outcomes Outcomes
Entry into the continuation phase required Entry into the continuation phase required a 50% reduction in baseline HRSD score a 50% reduction in baseline HRSD score by 8 weeks. An HRSD score of 10 or less by 8 weeks. An HRSD score of 10 or less had to be maintained for a period of 4 had to be maintained for a period of 4 weeks during the continuation phase prior weeks during the continuation phase prior to randomisation into the double-blind, to randomisation into the double-blind, placebo-controlled maintenance phase of placebo-controlled maintenance phase of the study. The continuation phase could the study. The continuation phase could be extended up to 20 weeks, depending be extended up to 20 weeks, depending on assessment scores. Recurrence during on assessment scores. Recurrence during the maintenance phase was defined as an the maintenance phase was defined as an HRSD score of 13 or over as well as meet-HRSD score of 13 or over as well as meeting DSM-III-R criteria for major depres-ing DSM-III-R criteria for major depressive disorder as determined by a trained sive disorder as determined by a trained psychiatrist. psychiatrist.
Analysis Analysis
Analysis was carried out independently of Analysis was carried out independently of the funding body. The initial analysis com-the funding body. The initial analysis compared clinical and demographic character-pared clinical and demographic characteristics of the experimental sample with istics of the experimental sample with individuals withdrawn or excluded from individuals withdrawn or excluded from the study before the maintenance phase. the study before the maintenance phase. Follow-up data are provided for partici-Follow-up data are provided for participants subsequently excluded because of pants subsequently excluded because of recurrence during the maintenance phase. recurrence during the maintenance phase. In the main analysis, primary outcome vari-In the main analysis, primary outcome variables were subjected to survival analyses ables were subjected to survival analyses using Kaplan-Meier and hazard ratio using Kaplan-Meier and hazard ratio calculations. The distribution of rate of calculations. The distribution of rate of recurrence across the maintenance phase recurrence across the maintenance phase is described. A Cox proportional hazards is described. A Cox proportional hazards regression model was used to explore regression model was used to explore the potential influence of baseline and the potential influence of baseline and experimental variables in determining experimental variables in determining outcome. outcome.
Ethical approval Ethical approval
The study was granted ethical approval by The study was granted ethical approval by the local ethics committee. Each participant the local ethics committee. Each participant was provided with written and verbal infor-was provided with written and verbal information. Informed consent was required mation. Informed consent was required prior to trial inclusion. Primary care physi-prior to trial inclusion. Primary care physicians were informed of the trial and cians were informed of the trial and provided with a full psychiatric assessment, provided with a full psychiatric assessment, care programme and regular updates care programme and regular updates concerning clinical progress, for each concerning clinical progress, for each participant. participant.
RESULTS
Study sample Study sample
Three hundred and eighteen persons ful-Three hundred and eighteen persons fulfilled the depression entry criteria. They filled the depression entry criteria. They had a mean age of 77.7 years (s.d. had a mean age of 77.7 years (s.d.¼7.1) 7.1) and a mean HRSD score of 20.4 (s.d. and a mean HRSD score of 20.4 (s.d.¼ 3.2). Sixty-four persons were subsequently 3.2). Sixty-four persons were subsequently excluded from entry into the treatment excluded from entry into the treatment phase of the trial: 28 refused consent, 9 phase of the trial: 28 refused consent, 9 were excluded because of severe, unstable were excluded because of severe, unstable physical illness, 7 took contraindicated physical illness, 7 took contraindicated drugs, 1 had had a previous adverse reac-drugs, 1 had had a previous adverse reaction to sertraline and 6 were excluded be-tion to sertraline and 6 were excluded because of protocol violations; the reasons cause of protocol violations; the reasons for 13 exclusions were unrecorded. The for 13 exclusions were unrecorded. The study population (those taking at least one study population (those taking at least one dose of sertraline and receiving at least dose of sertraline and receiving at least one follow-up visit) consisted of 254 per-one follow-up visit) consisted of 254 persons (65 men and 189 women) with a mean sons (65 men and 189 women) with a mean age of 77.6 years (s.d. age of 77.6 years (s.d.¼6.6). Of these, 141 6.6). Of these, 141 failed to meet the entry criteria for the failed to meet the entry criteria for the maintenance phase (Fig. 1 ). The remaining maintenance phase (Fig. 1 ). The remaining 113 participants were randomised to 113 participants were randomised to 4 9 3 4 9 3 receive sertraline ( receive sertraline (n n¼56) or placebo ( 56) or placebo (n n¼57; 57; Table 1 ). Recruitment source did not pre- Table 1 ). Recruitment source did not predict likelihood of entry into the mainte-dict likelihood of entry into the maintenance phase (Pearson nance phase (Pearson w w 2 2 ¼3.0, d.f. 3.0, d.f.¼3, 3, P P¼0.4). However, those not meeting main-0.4). However, those not meeting maintenance phase entry criteria had signifi-tenance phase entry criteria had significantly higher baseline HRSD scores (2.42, cantly higher baseline HRSD scores (2.42, 95% CI 1.10-3.74). 95% CI 1.10-3.74).
Of those who were withdrawn during Of those who were withdrawn during the maintenance phase, 84 consented to open the maintenance phase, 84 consented to open follow-up. These included people experien-follow-up. These included people experiencing recurrence and protocol violations. cing recurrence and protocol violations. Two-thirds of this group ( Two-thirds of this group (n n¼57) accepted 57) accepted subsequent antidepressant therapy of at least subsequent antidepressant therapy of at least 8 weeks duration: 12 (21%) achieved remis-8 weeks duration: 12 (21%) achieved remission (MADRS score of 6 or less), 19 (33%) sion (MADRS score of 6 or less), 19 (33%) remained depressed, and the remaining 26 remained depressed, and the remaining 26 (46%) had varying levels of improvement. (46%) had varying levels of improvement. Seventeen (20%) of the 84 died prior to the Seventeen (20%) of the 84 died prior to the end of the follow-up period of 2 years. end of the follow-up period of 2 years.
Trial drug dosage and medication Trial drug dosage and medication compliance compliance
Tablets were delivered to the participants' Tablets were delivered to the participants' homes, and tablet counts were conducted homes, and tablet counts were conducted at each assessment. Participants were at each assessment. Participants were maintained on the dosage that achieved maintained on the dosage that achieved remission of presenting episode: 73% of remission of presenting episode: 73% of the sertraline group and 75% of the pla-the sertraline group and 75% of the placebo group received 50 mg daily, while cebo group received 50 mg daily, while the others received 100 mg daily. None the others received 100 mg daily. None received 150 mg (or placebo equivalent) received 150 mg (or placebo equivalent) during the maintenance phase. during the maintenance phase.
Analysis of recurrence Analysis of recurrence
Kaplan-Meier survival analyses showed no Kaplan-Meier survival analyses showed no significant difference (log rank test 1.55, significant difference (log rank test 1.55, d.f. d.f.¼1, 1, P P¼0.21) between sertraline and 0.21) between sertraline and placebo in prevention of recurrence. The placebo in prevention of recurrence. The sertraline group had a cumulative survival sertraline group had a cumulative survival function of 39% with a median survival function of 39% with a median survival of 92 weeks. The placebo group had a of 92 weeks. The placebo group had a cumulative survival function of 31% with cumulative survival function of 31% with a median survival of 48 weeks (Table 2) . a median survival of 48 weeks (Table 2) . There was a reduction in risk of recurrence There was a reduction in risk of recurrence of 8.4% over 100 weeks for people taking of 8.4% over 100 weeks for people taking sertraline compared with those taking sertraline compared with those taking placebo during the maintenance phase. placebo during the maintenance phase.
Over half of those experiencing recur-Over half of those experiencing recurrence did so during the first 26 weeks of rence did so during the first 26 weeks of the maintenance phase: 15 (60%) in the the maintenance phase: 15 (60%) in the placebo group, 16 (57%) in the sertraline placebo group, 16 (57%) in the sertraline group. Approximately a quarter (32% group. Approximately a quarter (32% placebo and 16% sertraline) experienced placebo and 16% sertraline) experienced recurrence between 27 weeks and 52 recurrence between 27 weeks and 52 weeks. The remainder experienced recur-weeks. The remainder experienced recurrence during the second year of follow-up. rence during the second year of follow-up. We examined the relative rate of recurrence We examined the relative rate of recurrence across time, and compared the proportion across time, and compared the proportion of eligible participants experiencing a of eligible participants experiencing a recurrence at each assessment. Three main recurrence at each assessment. Three main 'peaks' were identified (at 15 weeks, 30 'peaks' were identified (at 15 weeks, 30 weeks and 50 weeks) at which 8% or more weeks and 50 weeks) at which 8% or more of eligible participants experienced re-of eligible participants experienced recurrence. However, at least three other currence. However, at least three other peaks (at 8 weeks, 64 weeks and 72 weeks) peaks (at 8 weeks, 64 weeks and 72 weeks) were identified at which 5-6% of eligible were identified at which 5-6% of eligible participants experienced a recurrence. participants experienced a recurrence.
Cox's regression analysis Cox's regression analysis
Clinical and demographic variables were Clinical and demographic variables were entered into a stepwise analysis (backwards entered into a stepwise analysis (backwards 4 9 4 4 9 4 elimination) to investigate models of recur-elimination) to investigate models of recurrence prediction. Eleven items were entered rence prediction. Eleven items were entered into the first stage of the regression. Of into the first stage of the regression. Of these, sertraline these, sertraline v.
v. placebo, MMSE score, placebo, MMSE score, length of presenting episode, previous length of presenting episode, previous number of episodes, Burvill scores (of number of episodes, Burvill scores (of which there are four separate sub-scores) which there are four separate sub-scores) and gender were dropped. Dosage of main-and gender were dropped. Dosage of maintenance medication was associated with tenance medication was associated with baseline severity of depression: high dosage baseline severity of depression: high dosage did not protect against recurrence. Age (in did not protect against recurrence. Age (in 5-year increments) and pre-randomisation 5-year increments) and pre-randomisation MADRS score were predictive of recur-MADRS score were predictive of recurrence (Table 3 ). Each 5-year increase in rence (Table 3 ). Each 5-year increase in age has a hazard ratio of 1.30 (95% CI age has a hazard ratio of 1.30 (95% CI 1.04-1.61). A one-point increase in pre-1.04-1.61). A one-point increase in prerandomisation (end of continuation phase) randomisation (end of continuation phase) MADRS score has a hazard ratio of 1.11 MADRS score has a hazard ratio of 1.11 (95% CI 1.02-1.20) for recurrence. (95% CI 1.02-1.20) for recurrence.
DISCUSSION DISCUSSION
This is the first maintenance study to This is the first maintenance study to challenge the assumption that the dosage challenge the assumption that the dosage of an antidepressant that achieves remis-of an antidepressant that achieves remission also provides protection against recur-sion also provides protection against recurrence. We examine our findings in terms rence. We examine our findings in terms of design limitations and in the context of design limitations and in the context of contemporaneous literature. of contemporaneous literature. , 1993) have been criticised for selection 1993) have been criticised for selection bias, excluding a large percentage of the bias, excluding a large percentage of the eligible sample and not supplying infor-eligible sample and not supplying information about those who were excluded or mation about those who were excluded or follow-up of those who experienced recur-follow-up of those who experienced recurrence during the trial. We recruited partici-rence during the trial. We recruited participants from four different sources, reducing pants from four different sources, reducing the likelihood of selection bias. Recruit-the likelihood of selection bias. Recruitment source did not influence eligibility to ment source did not influence eligibility to enter the maintenance phase and was not enter the maintenance phase and was not associated with outcome. In this study, associated with outcome. In this study, relatively few people were excluded relatively few people were excluded because of concomitant physical illness because of concomitant physical illness ( (n n¼9). However, analysis demonstrates 9). However, analysis demonstrates that those with more severe depression that those with more severe depression were excluded from entry into the main-were excluded from entry into the maintenance phase. Consequently, our findings tenance phase. Consequently, our findings reflect the prophylactic efficacy of thera-reflect the prophylactic efficacy of therapeutic doses of sertraline in older people peutic doses of sertraline in older people in the community who are suffering from in the community who are suffering from mild to moderate severity of DSM-III-R mild to moderate severity of DSM-III-R major depressive disorder. Of those who major depressive disorder. Of those who did experience recurrence, two-thirds did experience recurrence, two-thirds accepted a second antidepressant or accepted a second antidepressant or increased dose of sertraline, of whom under increased dose of sertraline, of whom under a quarter had a good outcome, while the a quarter had a good outcome, while the remainder showed some improvement. remainder showed some improvement. However, the mortality rate over 2 years However, the mortality rate over 2 years was high in this group. was high in this group.
Limitations of the study Limitations of the study
The design of this study may be The design of this study may be criticised because of its relatively short criticised because of its relatively short continuation phase. Guidelines suggest that continuation phase. Guidelines suggest that the continuation phase should be up to 6 the continuation phase should be up to 6 months' duration, based on the assumption months' duration, based on the assumption that a depressive episode lasts 6-9 months that a depressive episode lasts 6-9 months in those treated as out-patients (Kupfer & in those treated as out-patients (Kupfer & Frank, 1992) . However, as in the study by Frank, 1992). However, as in the study by Klysner Klysner et al et al (2002), there was no signifi-(2002), there was no significant peak of recurrence within the first cant peak of recurrence within the first few months of the maintenance phase in few months of the maintenance phase in the placebo group, as would be expected the placebo group, as would be expected if participants were experiencing relapse if participants were experiencing relapse as opposed to recurrence. as opposed to recurrence.
The study may also be criticised on the The study may also be criticised on the grounds of potential type II error. The grounds of potential type II error. The power analysis indicated that 60 partici-power analysis indicated that 60 participants should be recruited into each arm of pants should be recruited into each arm of the post-randomisation phase. Owing to the post-randomisation phase. Owing to protocol violations identified after recruit-protocol violations identified after recruitment was closed, 6 persons (0.05% of the ment was closed, 6 persons (0.05% of the study sample) were subsequently excluded study sample) were subsequently excluded from the analyses. Statistical modelling from the analyses. Statistical modelling indicated that the inclusion of these indivi-indicated that the inclusion of these individuals in the appropriate experimental arms duals in the appropriate experimental arms and allocating them to the outcome that and allocating them to the outcome that favours drug efficacy compared with favours drug efficacy compared with placebo did not significantly influence the placebo did not significantly influence the results. Our study is comparable in size to results. Our study is comparable in size to that of Klysner that of Klysner et al et al (2002), which was of (2002), which was of a similar design, evaluating an anti-a similar design, evaluating an antidepressant from the same class. Other depressant from the same class. Other studies in this age group that are of similar studies in this age group that are of similar design are approximately half the size of design are approximately half the size of our study. Ardern our study. Ardern Poor compliance and sub-therapeutic blood Poor compliance and sub-therapeutic blood levels are thought to explain up to 50% of levels are thought to explain up to 50% of the recurrence in that study. The authors the recurrence in that study. The authors also suggest that sub-therapeutic blood also suggest that sub-therapeutic blood levels explain the negative findings of other, levels explain the negative findings of other, smaller studies (Georgotas smaller studies (Georgotas et al et al, 1989) , 1989) examining the prophylactic efficacy of the examining the prophylactic efficacy of the same drug. In a small study examining the same drug. In a small study examining the efficacy of lithium and cognitive-efficacy of lithium and cognitivebehavioural therapy in the prevention of behavioural therapy in the prevention of recurrence and relapse, Wilson recurrence and relapse, Wilson et al et al (1995) noted that poor drug compliance (1995) noted that poor drug compliance resulting in low serum lithium levels resulting in low serum lithium levels confounded the findings. confounded the findings.
We believe that low dosage is unlikely We believe that low dosage is unlikely to be responsible for the findings of our to be responsible for the findings of our study. Participants were maintained on the study. Participants were maintained on the dosage of sertraline at which they achieved dosage of sertraline at which they achieved remission; three-quarters took 50 mg daily, remission; three-quarters took 50 mg daily, which is recognised as the optimum dose which is recognised as the optimum dose for treatment (Preskorn & Lane, 1995) , for treatment (Preskorn & Lane, 1995) , 4 9 5 4 9 5 and about a quarter were treated with and about a quarter were treated with 100 mg. High dosage was associated with 100 mg. High dosage was associated with increased severity of index depression and increased severity of index depression and did not have an increased protective effect did not have an increased protective effect in terms of outcome. Compliance is more in terms of outcome. Compliance is more difficult to monitor. Compliance was difficult to monitor. Compliance was enhanced through domiciliary delivery of enhanced through domiciliary delivery of medication and supportive, ongoing coun-medication and supportive, ongoing counselling, emphasising the importance of selling, emphasising the importance of medication, with tablet counting at each medication, with tablet counting at each assessment. Analysis failed to demonstrate assessment. Analysis failed to demonstrate any difference between tablet returns in any difference between tablet returns in those experiencing recurrence compared those experiencing recurrence compared with those who remained asymptomatic in with those who remained asymptomatic in the sertraline group. There was no differ-the sertraline group. There was no difference between those who received sertraline ence between those who received sertraline and those who received placebo in terms of and those who received placebo in terms of compliance monitoring. Blanchard compliance monitoring. Blanchard et al et al (1999) demonstrated the importance of (1999) demonstrated the importance of generic nurse support in the longer-term generic nurse support in the longer-term management of depression in older com-management of depression in older community residents. The follow-up in this munity residents. The follow-up in this study was intense, with regular home visits study was intense, with regular home visits augmented by telephone contact. Members augmented by telephone contact. Members of both placebo and experimental groups of both placebo and experimental groups received similar support in terms of nature received similar support in terms of nature and number of contacts during the experi-and number of contacts during the experimental period. It is unlikely that differential mental period. It is unlikely that differential support influenced the findings. support influenced the findings.
Our findings in context Our findings in context
We have found two studies that have We have found two studies that have examined the prophylactic efficacy of ser-examined the prophylactic efficacy of sertraline. Doogan & Caillard (1992) found traline. Doogan & Caillard (1992) found that sertraline was more effective than that sertraline was more effective than placebo in preventing recurrence in 144 placebo in preventing recurrence in 144 subjects over 44 weeks. Keller (1998) subjects over 44 weeks. Keller (1998) found similar results in a younger popu-found similar results in a younger population over 76 weeks. However, the design lation over 76 weeks. However, the design of both these studies included a facility to of both these studies included a facility to increase maintenance dosage (preserving increase maintenance dosage (preserving masking integrity) in people who were masking integrity) in people who were thought to be showing early evidence of re-thought to be showing early evidence of recurrence during the double-blind, placebo-currence during the double-blind, placebocontrolled phase. An analysis of presented controlled phase. An analysis of presented data suggests that a significant proportion data suggests that a significant proportion of those experiencing potential recurrence of those experiencing potential recurrence benefited from a subsequent dosage benefited from a subsequent dosage increase in each study. These findings are increase in each study. These findings are reflected in the 'treatment of recurrence' reflected in the 'treatment of recurrence' study by Franchini study by Franchini et al et al (2000) , who found (2000), who found that increasing the dosage of sertraline had that increasing the dosage of sertraline had a therapeutic role in the management of re-a therapeutic role in the management of recurrence in people with depression who currence in people with depression who were already taking the drug. Our study were already taking the drug. Our study design did not have the facility of increasing design did not have the facility of increasing maintenance dosage when early signs of re-maintenance dosage when early signs of recurrence became obvious; participants were currence became obvious; participants were maintained at the dosage of sertraline that maintained at the dosage of sertraline that achieved remission of the presenting epi-achieved remission of the presenting episode. A subsequent search of the Cochrane sode. A subsequent search of the Cochrane Database of randomised, controlled trials Database of randomised, controlled trials failed to generate any evidence that the failed to generate any evidence that the dosage of sertraline required to achieve dosage of sertraline required to achieve remission has prophylactic efficacy and that remission has prophylactic efficacy and that enhanced dosage is probably required for enhanced dosage is probably required for maintenance treatment. maintenance treatment.
Predictive variables Predictive variables
As in our study, Reynolds As in our study, Reynolds et al et al (1999 Reynolds et al et al ( ) (1999 found an association between increased found an association between increased age and recurrence. Notably, these obser-age and recurrence. Notably, these observations are independent of the number of vations are independent of the number of preceding episodes experienced by the indi-preceding episodes experienced by the individual. Follow-up studies of patients vidual. Follow-up studies of patients referred to secondary services have demon-referred to secondary services have demonstrated a mixed association between acute strated a mixed association between acute and chronic physical illness and handicap and chronic physical illness and handicap (Burvill (Burvill et al et al, 1991) . We were unable to , 1991). We were unable to demonstrate any significant correlation demonstrate any significant correlation between these variables and outcome. between these variables and outcome. Again, our findings concur with those of Again, our findings concur with those of Reynolds Reynolds et al et al (1999) , who examined these (1999), who examined these issues in the context of a randomised, con-issues in the context of a randomised, controlled trial. Our finding that following trolled trial. Our finding that following remission, residual depressive symptoms remission, residual depressive symptoms predict poor outcome in terms of recur-predict poor outcome in terms of recurrence has been found in other treatment-rence has been found in other treatmentcontrolled studies (Faravelli controlled studies (Faravelli et al et al, 1986) . , 1986).
Clinical and research implications Clinical and research implications
A number of research issues are generated A number of research issues are generated by these findings. First, there is no doubt by these findings. First, there is no doubt that sertraline is a relatively safe and thera-that sertraline is a relatively safe and therapeutically active drug (Finkel peutically active drug (Finkel et al et al, 2000) , 2000) which has been examined in the context which has been examined in the context of prophylactic treatment. Despite these la-of prophylactic treatment. Despite these later studies (Keller, 1998; Finkel ter studies (Keller, 1998; Finkel et al et al, 2000) , 2000) being positive, our negative findings are being positive, our negative findings are consistent when study design is taken into consistent when study design is taken into account. In this study we specifically account. In this study we specifically examined the prophylactic efficacy of examined the prophylactic efficacy of sertraline prescribed at the dosage required sertraline prescribed at the dosage required to achieve remission. This differs from to achieve remission. This differs from other studies, which clearly demonstrate other studies, which clearly demonstrate the prophylactic efficacy of sertraline pro-the prophylactic efficacy of sertraline provided that the dosage is increased over vided that the dosage is increased over and above that required to achieve remis-and above that required to achieve remission of the presenting episode. These nega-sion of the presenting episode. These negative findings are important. It is apparent tive findings are important. It is apparent that in the absence of evidence, it cannot that in the absence of evidence, it cannot be assumed that the dosage of antidepres-be assumed that the dosage of antidepressant required to achieve remission offers sant required to achieve remission offers protection against recurrence or relapse: in protection against recurrence or relapse: in the case of sertraline, the effective prophy-the case of sertraline, the effective prophylactic dosage is likely to be greater than lactic dosage is likely to be greater than the therapeutic dosage. Second, in compar-the therapeutic dosage. Second, in comparing this study with other studies conducted ing this study with other studies conducted on similar populations it is evident that on similar populations it is evident that antidepressants differ in terms of mainte-antidepressants differ in terms of maintenance efficacy. A review of the literature nance efficacy. A review of the literature indicates that this is not a class-specific phe-indicates that this is not a class-specific phenomenon and emphasises the importance of nomenon and emphasises the importance of randomised, controlled trials in establishing randomised, controlled trials in establishing prophylactic efficacy (and dosage) before prophylactic efficacy (and dosage) before new antidepressants are routinely employed new antidepressants are routinely employed in this fashion. Third, it is evident that in this fashion. Third, it is evident that extreme age is associated with an increased extreme age is associated with an increased risk of recurrence of depression over 2 risk of recurrence of depression over 2 years -in the study by Reynolds years -in the study by Reynolds et al et al (1999) , 3 years. It is important in future (1999), 3 years. It is important in future that maintenance trials are developed to that maintenance trials are developed to accommodate these issues, bearing in mind accommodate these issues, bearing in mind the relatively high levels of morbidity and the relatively high levels of morbidity and suicide in this age group. suicide in this age group.
From a clinical perspective, three speci-From a clinical perspective, three specific recommendations can be drawn from fic recommendations can be drawn from our findings. First, this study draws atten-our findings. First, this study draws attention to the particular vulnerability of very tion to the particular vulnerability of very old people with depression living in the old people with depression living in the community. It is evident that emphasis community. It is evident that emphasis must be placed on maximising symptom must be placed on maximising symptom control during the treatment phase. Even control during the treatment phase. Even minor (sub-syndromal) residual symptoms minor (sub-syndromal) residual symptoms are predictive of poor outcome in terms of are predictive of poor outcome in terms of recurrence. This warrants an aggressive recurrence. This warrants an aggressive and closely observed treatment plan. and closely observed treatment plan. Second, it is also apparent that the very Second, it is also apparent that the very old are particularly vulnerable to recur-old are particularly vulnerable to recurrence. This is independent of the number rence. This is independent of the number of previous episodes experienced by the of previous episodes experienced by the individual. Consequently, these people individual. Consequently, these people should be encouraged to take long-term should be encouraged to take long-term maintenance medication, irrespective of maintenance medication, irrespective of the number of previous episodes. Third, it the number of previous episodes. Third, it is not safe to assume (in the absence of is not safe to assume (in the absence of evidence) that the therapeutically active evidence) that the therapeutically active dose of an antidepressant that promoted dose of an antidepressant that promoted remission has prophylactic efficacy. In-remission has prophylactic efficacy. Increased dosage may be required in the creased dosage may be required in the context of long-term, closely followed-up context of long-term, closely followed-up therapy, with counselling and compliance therapy, with counselling and compliance monitoring. monitoring. 
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